A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression: The MIND1 Trial
Summary
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an alternative. Repetitive transcranial magnetic stimulation (rTMS) and more recently, theta-burst stimulation (TBS), are the noninvasive brain stimulation modalities with the largest evidence base in MDD.
Why it matters
This trial represents an important advancement in neurotechnology for treating Treatment Resistant Depression. If successful, the device-based intervention could provide a new therapeutic option for patients who have not responded adequately to conventional treatments or therapies. The study results may inform future regulatory approval pathways and establish clinical precedent that could benefit broader patient populations with similar conditions.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial